Microsoft PowerPoint - 17 Introduction Valentini [Compatibil

110 / 1084

• RTOG 85-01 – 1999 T1-3 N0-1M0 Low third: n.a.
• RTOG 85-01 – 1999 129 pts Adeno 21.4%
• RTOG 85-01 – 1999 SVV Benefit (RTCT vs RT Alone)
• RTOG 85-01 - 1999 Phase III Trial RT (64Gy) vs RTCT (50Gy)
 Does dose impact long term outcome?
• INT 0123 – 2002 T1-T4 N0-1M0 Low third: n.a.
• INT 0123 – 2002 218 pts Hystotype: n.a.
• INT 0123 – 2002 NO SVV Benefit
• INT 0123 - 2002 Phase III Trial RTCT (50Gy) vs RTCT (65Gy)
Cooper et al; - JAMA – 1999 (USA)
Minsky et al; JCO 2002 (USA)